CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 105 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01795248
NCT01795248Phase 4Completed
CompareCT.gov

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus

Tina Vilsboll·interventional·Posted Feb 20, 2013·Updated Nov 4, 2020

In Brief

A Phase 4 clinical trial evaluating Liraglutide and Placebo for Gestational Diabetes Mellitus. Completed, enrolled 105 participants across 1 site.

Detailed Summary

It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGestational Diabetes Mellitus
CountriesDenmark
CollaboratorsNovo Nordisk A/S, Rigshospitalet, Denmark, Hvidovre University Hospital, Herlev Hospital, Hillerod Hospital, Denmark, University of Copenhagen, The Novo Nordisk Foundation Center for Basic Metabolic Research, Aarhus University Hospital

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2013
Enrollment StartJul 1, 2012
Primary CompletionSep 1, 2019
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 13.4 years ago

Interventions

Liraglutidedrug

1.8 mg liraglutide

Placebodrug

Liraglutide without the GLP-1 analogue